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Objectives. We sought to compare primary coronary angio-
plasty and thrombolysis as treatment for low risk patients with an
acute myocardial infarction.
Background. Primary coronary angioplasty is the most effective
reperfusion therapy for patients with acute myocardial infarction;
however, intravenous thrombolysis is easier to apply, more widely
available and possibly more appropriate in low risk patients.
Methods. We stratified 240 patients with acute myocardial
infarction at admission according to risk. Low risk patients (n 5
95) were randomized to primary angioplasty or thrombolytic
therapy. The primary end point was death, nonfatal stroke or
reinfarction during 6 months of follow-up. Left ventricular ejec-
tion fraction and medical charges were secondary end points.
High risk patients (n 5 145) were treated with primary angio-
plasty.
Results. In low risk patients, the incidence of the primary
clinical end point (4% vs. 20%, p < 0.02) was lower in the group
with primary coronary angioplasty than in the group with throm-
bolysis, because of a higher rate of reinfarction in the latter group.
Mortality and stroke rates were low in both treatment groups.
There were no differences in left ventricular ejection fraction or
total medical charges. High risk patients had a 14% incidence rate
of the primary clinical end point.
Conclusions. Simple clinical data can be used to risk-stratify
patients during the initial admission for myocardial infarction.
Even in low risk patients, primary coronary angioplasty results in
a better clinical outcome at 6 months than does thrombolysis and
does not increase total medical charges.
(J Am Coll Cardiol 1997;29:908–12)
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Primary angioplasty, defined as angioplasty for acute myocar-
dial infarction without prior or concomitant thrombolytic
therapy, results in a higher patency rate of the infarct-related
vessel, smaller enzymatic infarct size, better preserved left
ventricular function and better clinical outcome when com-
pared with intravenous thrombolytic therapy (1–4). However,
the logistic burden of offering primary angioplasty to all
patients with acute myocardial infarction is considerable (5–
12). Previous studies (1,7,13) have shown that the increased
benefit of primary angioplasty over that of thrombolytic ther-
apy has been found in particular in high risk patients but is less
certain in low risk patients. Therefore, we randomized patients
at low risk to thrombolytic therapy or primary angioplasty.
Several retrospective analyses (1,7,14–17) have shown that
simple clinical and electrocardiographic (ECG) variables, as-
sessed during initial presentation, can be used to stratify
patients with acute myocardial infarction according to risk. We
describe the clinical outcome and cost-effectiveness of primary
angioplasty versus thrombolysis in low risk patients and com-
pare these findings with those in a concomitant series of
patients at high risk of untoward events.
Methods
Study patients. Inclusion criteria were symptoms of myo-
cardial infarction for .30 min, within 6 h of symptom onset or
between 6 and 24 h if there were signs and symptoms of
ongoing ischemia with $0.1 mV ST segment elevation in more
than two leads. No specific exclusion criteria were used. Only
patients with a life expectancy of ,6 months or conditions
resulting in severe impairment of quality of life were excluded.
Oral informed consent was obtained from all patients. The trial
was approved by the committee on ethics and research at our
institution. During the enrollment period, 17 patients who
fulfilled the entry criteria did not participate in the study
because of patient refusal or preference of the patient or
physician, or both, for a specific therapy.
Sample size. Assuming an incidence rate of death and
nonfatal stroke of 3% and of nonfatal reinfarction of 12% after
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6 months of follow-up (17–22) for low risk patients treated with
thrombolytic therapy, and a 0.4 relative risk of the primary
clinical end point (death, nonfatal stroke or reinfarction), a
sample size of 296 low risk patients was calculated (one-sided
alpha level of 0.05, and a power of 80%), with an expected total
of .500 patients in the trial. Interim analysis was planned after
inclusion of 150 patients.
Statistical analysis. All end points were analyzed accord-
ing to the intention to treat principle. Results are expressed as
absolute numbers and mean values 6 SD. Differences between
group means were tested by unpaired Student t test. A
chi-square method or Fisher exact test was used to test
differences between proportions. Statistical significance was
defined as a p value ,0.05.
Randomization and stratification. Between May 1993 and
April 1995, 240 patients were considered for this trial. All
patients were classified as at high or low risk. Patients were
regarded as at high risk if one of the following criteria were
present: 1) contraindications for thrombolytic therapy (14,16);
2) Killip class $2 (1,13); 3) ECG evidence of anterior wall
infarction or evidence of extensive nonanterior infarction
defined as eight or more leads with $0.1 mV ST elevation or
depression, or both (1,13,17). All high risk patients underwent
immediate coronary angiography and were treated with pri-
mary angioplasty if the coronary anatomy was suitable. The low
risk patients were randomly allocated by telephone to either
primary angioplasty or intravenous streptokinase, after they
gave informed consent.
Treatment. All patients received heparin intravenously and
aspirin. Beta-adrenergic blocking agents were given unless
contraindicated. All patients with clinical signs of heart failure
or a left ventricular ejection fraction ,40% received
angiotensin-converting enzyme inhibitors. Angioplasty was
performed by standard techniques. Angioplasty success was
defined as a residual lesion of ,50% in the infarct-related
vessel, with Thrombolysis in Myocardial Infarction (TIMI)
grade 3 flow. Thrombolytic therapy consisted of 1.5 million IU
of streptokinase. Patients given thrombolytic therapy had
coronary angiography between day 3 and day 7, or immediately
if symptoms and signs of recurrent ischemia appeared. Patients
treated with primary angioplasty underwent follow-up coro-
nary angiography 3 to 6 months after angioplasty. Additional
revascularization procedures were performed for left main and
extensive triple-vessel coronary artery disease depending on
coronary anatomy. In patients with less extensive coronary
artery disease, revascularization during follow-up depended on
angina and noninvasive evidence of myocardial ischemia.
Primary end point. This was defined as death, nonfatal
stroke or reinfarction at 6 months. All patients with possible or
suspected stroke were reviewed by a neurologist and under-
went a computed tomography scan. Reinfarction was defined
as a second episode of chest pain of $30 min duration with a
second creatine kinase (CK) rise to more than two times the
upper limit of normal, or an increase of .200 U/liter over the
previous value if the level had not dropped below the upper
limit of normal, and either concomitant ST-T wave changes or
new Q waves (3).
Secondary end points. The two secondary end points were
left ventricular ejection fraction and total medical charges at 6
months. 1) Left ventricular ejection fraction was measured with
a radionuclide technique at day 5 and at 6 months. The
multigated equilibrium method was used after in vivo labeling
of red cells with 99mTc pertechnetate (3) using a gamma
camera (General Electric) with a low energy, all purpose,
parallel-hole collimator. Global ejection fraction was calcu-
lated automatically by computer (Star View, General Electric)
with the PAGE program. The data on ejection fraction were
analyzed by a nuclear medicine specialist who had no knowl-
edge of the clinical data.
2) Total medical charges at 6 months were calculated by
using estimates of unit costs concerning all aspects of medical
care, as previously described (23–25). In the Dutch medical
system the patient pays the charges of the hospital and those of
independent physicians and the pharmacy; health insurance
covers almost all of these expenses. Charges were considered
from the perspective of the patient. This methodology has
been described (25).
Results
After complete evaluation of the first 150 patients (26), and
after consultation with the institution’s committee on ethics
and research, a decision was made to stop the trial. Of these
150 patients, 73 were at low risk and were randomized to
primary angioplasty or streptokinase. The interim results indi-
cated that primary coronary angioplasty in low risk patients
facilitated early discharge and did not result in higher medical
charges (27). Subsequently, a general policy of primary coro-
nary angioplasty was adopted. At completion of the trial a total
of 240 patients had been enrolled.
Baseline clinical and angiographic characteristics are shown
in Table 1. In the low risk group randomized to angioplasty the
proportion of patients with multivessel disease was higher than
in the thrombolysis group; otherwise, the patient groups were
well matched. The design of the trial resulted in a high
proportion of low risk patients with the right coronary artery as
the infarct-related vessel, whereas the left anterior descending
coronary artery was usually the infarct-related vessel in the
high risk patients.
Of the total of 240 patients, 95 (39%) were considered at
low risk; 50 of the 95 patients were randomized to thrombolytic
therapy and received this treatment. The time from hospital
admission to start of the streptokinase infusion was 29 6
17 min. Forty-five patients were randomized to primary coro-
nary angioplasty, and all underwent immediate coronary an-
Abbreviations and Acronyms
CK 5 creatine kinase
ECG 5 electrocardiographic
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giography that was followed by primary angioplasty in 92%
with procedural success in 93%. The time from hospital
admission to the first balloon inflation was 68 6 21 min. In
three patients a conservative initial strategy was followed as
spontaneous reperfusion of the infarct-related vessel was evi-
dent on the angiogram; one patient with left main coronary
artery disease had emergency coronary artery bypass grafting.
During the 6-month follow-up period, 13% of the low risk
patients underwent bypass grafting for triple-vessel or left main
coronary artery disease.
Of the total of 240 patients, 145 (61%) had one or more of
the high risk characteristics. High risk patients with one high
risk characteristic (n 5 111) had a 10% incidence of the
primary clinical end point; those with more than one high risk
characteristic (n 5 34) had a 29% incidence. Additional
revascularization procedures and clinical outcome at 6 months
are shown in Table 2.
Primary end point. The primary end point of death, fatal
stroke or reinfarction was reached in 4% of low risk patients
randomized to angioplasty in contrast to 20% in low risk
patients randomized to thrombolytic therapy (relative risk
0.19, 95% confidence interval 0.04 to 0.90, p , 0.02). Only one
low risk patient (1%) died from cardiac rupture (at the age of
75 years, 5 days after failed primary coronary angioplasty).
Three patients had an ischemic stroke, 5, 7 and 14 days,
respectively, after the acute event, and none of these strokes
were related to the initial therapy. There were no strokes due
to intracerebral hemorrhage. Eight of the low risk patients
randomized to streptokinase had a reinfarction. All of these
patients were readmitted to the coronary care unit, had ST-T
abnormalities and CK elevation, and six of these eight had new
Q waves. Five of the eight reinfarctions occurred within the 1st
week after randomization. There were no reinfarctions in low
risk patients randomized to primary angioplasty. The incidence
of the primary clinical end point was lower in high risk patients
treated with primary angioplasty (14%) than in the low risk
patients assigned to thrombolysis, primarily because of a lower
reinfarction rate in the high risk group.
Secondary end points. Left ventricular ejection fraction was
measured in 93 (98%) of the 95 low risk patients and in 116
(80%) of the 145 high risk patients. At 6 months left ventric-
ular ejection fraction in the low risk angioplasty group was
51 6 9% and 48 6 10% in the thrombolysis group (p 5 0.11).
It was lower in the high risk group (43 6 11%).
Total medical charges at 6 months were lower in the low than
in the high risk group. There was no difference in total
charges/patient or total charges/survivor between the two low
risk groups, although the charges/event-free survivor were
lower in the angioplasty group (Table 3).
Discussion
Previous studies (1–7) have shown that primary coronary
angioplasty offers certain advantages over thrombolytic ther-
apy. High risk patients treated with primary angioplasty have a
lower mortality rate and a lower risk of intracranial hemor-
rhage. Our study shows that low risk patients benefit in terms
Table 1. Baseline Clinical and Angiographic Characteristics
Low Risk Group
(n 5 95)
High Risk
Group
(n 5 145)
Angioplasty
(n 5 45)
Thrombolysis
(n 5 50)
Age (yr) 63 6 11 59 6 12 62 6 12
Male 80% 74% 74%
Previous MI 18% 20% 15%
Anterior MI 0% 0% 63%
Killip class $2 0% 0% 28%
Contraindications for thrombolysis 0% 0% 8%
Infarct-related vessel
LMCA 0% 0% 3%
LAD 0% 0% 54%
RCA 85% 92% 30%
LCx 13% 8% 10%
Graft 2% 0% 2%
Multivessel disease* 71% 50% 57%
*Defined as at least one 50% lesion in a major noninfarct-related coronary
artery. Data are presented as mean value 6 SD or percent of patients. LAD 5
left anterior descending coronary artery; LCx 5 left circumflex coronary artery;
LMCA 5 left main coronary artery; MI 5 myocardial infarction; RCA 5 right
coronary artery.
Table 2. Results at 6 Months
Low Risk Group
(n 5 95)
High Risk
Group
(n 5 145)
Angioplasty
(n 5 45)
p
Value*
Thrombolysis
(n 5 50)
Revascularization
procedures
CABG 6 (13%) 1 7 (14%) 23 (16%)
(re)PTCA 9 (20%) , 0.001 30 (60%) 20 (14%)
Clinical outcome
Death 1 (2%) 0.47 0 (0%) 16 (11%)
Stroke 1 (2%) 1 2 (4%) 0 (0%)
Reinfarction 0 (0%) , 0.01 8 (16%) 4 (3%)
Primary end
point†
2 (4%) , 0.02 10 (20%) 20 (14%)
*Comparing the angioplasty and thrombolysis low risk groups. †Defined as
death, nonfatal stroke or reinfarction within 6 months. Data are presented as
number (%) of patients. CABG 5 coronary artery bypass grafting; (re)PTCA 5
initial or repeat percutaneous transluminal coronary angioplasty.
Table 3. Total Medical Charges in Dutch Guilders
Low Risk Group
(n 5 95)
High Risk Group
(n 5 145)
Angioplasty
(n 5 45)
Thrombolysis
(n 5 50)
All patients 22.808 22.437 29.467
Survivors 23.327 22.895 33.122
Event-free survivors 23.869 28.765 34.182
Charges were calculated as previously described (23–25).
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of a lower risk of reinfarction, without an increase in total
medical charges. During long-term follow-up, nonfatal rein-
farction has been shown (28) to have independent prognostic
information.
Streptokinase. The Global Utilization of Streptokinase
and TPA for Occluded arteries (GUSTO) data (29,30) have
shown that thrombolytic therapy with front-loaded tissue plas-
minogen activator is more effective than therapy with strep-
tokinase, with a higher 90-min patency rate and a lower
mortality rate. However, in low risk patients the cost-
effectiveness of tissue plasminogen activator is less than that of
streptokinase (31,32). The main advantage of primary angio-
plasty over thrombolysis in low risk patients is the lesser risk of
reinfarction. In this regard the choice of thrombolytic agent is
irrelevant. A detailed analysis of the Gruppo Italiano per
lo Studio della Sopravvivenza nell’Infarto Miocardico II
(GISSI-2) working group has illustrated the difficulties in
predicting reinfarction, but they did not find a difference
between these two thrombolytic agents in the rate of reinfarc-
tion (33). There is a small difference in the risk of stroke
between these two drugs in favor of streptokinase (34). Finally,
the benefits of primary angioplasty over thrombolytic therapy
exceed the survival advantage of one thrombolytic agent over
the other by an order of magnitude.
Risk stratification. Many retrospective analyses (13–17)
have shown that patients with acute myocardial infarction can
be stratified with regard to risk on the basis of clinical and
ECG data available on initial presentation. Our data confirm
that patients classified as low risk do have a low risk for
untoward events up to 6 months, with a mortality rate of only
1%. With our criteria only 40% of patients were considered to
be at low risk, a lower proportion than we anticipated. In
particular, patients with contraindications for thrombolytic
therapy and patients in higher Killip classes are often excluded
from reperfusion trials, whereas in our trial almost all patients
with acute ST segment elevation myocardial infarction were
included. The most important limitation of risk stratification
during acute myocardial infarction is the inability to predict
recurrent myocardial infarction (7,33). Angiographic studies
have documented a reocclusion rate of the infarct-related
coronary artery in up to 30% of the patients after successful
thrombolytic therapy (19,20), whereas reocclusion after pri-
mary angioplasty is rare (4,35). A recent overview (22) con-
firms that recurrent myocardial ischemia and reinfarction are
less frequent after primary angioplasty than after thrombolytic
therapy.
Study limitations. Only a limited number of patients were
included in our trial. It is therefore possible that certain less
pronounced differences between angioplasty and thrombolytic
therapy in low risk patients do not show up in our results, and
the confidence intervals of the relative risk reduction are wide.
Therefore, although we found that the risk of reinfarction is
lower after primary angioplasty, the magnitude of this effect is
not clear. The diagnosis of reinfarction can be difficult early
after reperfusion therapy for acute myocardial infarction. For
this reason we required a second episode of chest pain with
ST-T segment changes and enzymatic confirmation before this
diagnosis was made, and most of these patients had new Q
waves. Although another strategy may also prevent recurrent
infarction—thrombolysis followed by angiography and inter-
vention a few days later, as has recently been suggested by the
DANish trial in Acute Myocardial Infarction (DANAMI)
study (36)—many reinfarctions occur early and can therefore
not be prevented by this approach.
Conclusions and clinical implications. Simple clinical
data, readily available during the 1st 15 min of hospital
admission for acute myocardial infarction, can be used to
stratify patients according to risk, and the results can be
incorporated in the therapeutic strategy. Even in patients with
a low risk of adverse events, primary coronary angioplasty
results in a better clinical outcome, in particular a lower
reinfarction rate, at 6 months than does thrombolytic therapy
and it does not cause an increase in total medical charges. In
hospitals with an existing infrastructure for interventional
cardiology all patients with symptoms of acute myocardial
infarction and ST segment elevation should be offered imme-
diate coronary angiography and primary coronary angioplasty.
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